These findings underscore Gal-1 as a promising therapeutic target for addressing prostate cancer progression beyond drug resistance, enhancing the potential of inhibitors like LLS30 in treating advanced prostate cancer. The gene discussed is LGALS1; the disease is Familial prostate cancer.